EUVIMEDEUVIMED entdecken
Crossref

Gemfibrozil, a lipid‐lowering drug, improves hepatorenal damages in a mouse model of aging

Elham Hakimizadeh, Saeedeh Tadayon, Mohammad Yasin Zamanian iD, Afsaneh Soltani, Lydia Giménez-Llort, Mahsa Hassanipour iD, Iman Fatemi iD

Fundamental & Clinical Pharmacology · 2023

DOI: 10.1111/fcp.12865 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2023. Verfasst von Elham Hakimizadeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Hauptthemen laut MEDLINE: Gemfibrozil, Aging. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Rafsanjan University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gemfibrozil (GFZ) is a medication of the fibrate category with agonistic effects on peroxisome proliferator‐activated receptor‐α (PPAR‐α) and is effective for hypertriglyceridemia and mixed dyslipidemia. This agent also has anti‐inflammatory and antioxidant properties. The current study investigated the effects of GFZ on hepatorenal damages in a D‐galactose (D‐gal)‐induced aging model. We used 28 male mice, which were equally and randomly divided into four groups as follows: normal, D‐gal (150 mg/kg/day; intraperitoneal [i.p.], for 6 weeks), GFZ (100 mg/kg/day GFZ, orally [p.o.] for 6 weeks), and the combined D‐gal + GFZ. Liver and kidney function indices were measured as serum creatinine, blood urine nitrogen, alanine aminotransferase, and aspartate aminotransferase. Oxidative stress in hepatic and renal tissue was evaluated through malondialdehyde, superoxide dismutase, and glutathione peroxidase levels. Finally, the liver and kidney tissues were assessed for histopathological lesions. The results showed that D‐gal‐induced aging leads to abnormalities in liver and kidney function indices. D‐gal also induced significant oxidative stress and histopathological lesions in these organs. GFZ improved function indices and oxidative stress compared to the D‐gal‐treated animals. Histological evaluations of the liver and kidney also confirmed these results. These data provide evidence for the potential therapeutic of GFZ in clinical practice for mitigating the hepatorenal damages of aging.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemfibrozilAgingMaleMiceAnimalsLiverOxidative StressAntioxidantsDisease Models, AnimalHypolipidemic Agents

Stichwörter der Autor:innen

aginggemfibrozilkidneylivermicetranslational research

Substanzen

GemfibrozilAntioxidantsHypolipidemic Agents

Autor:innen und Institutionen

  • Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
  • Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
  • Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
  • School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Institut de Neurociències & Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.

ORCID-Profile: Mohammad Yasin Zamanian, Mahsa Hassanipour, Iman Fatemi

Förderung

  • Rafsanjan University of Medical Sciences

Zitieren

APA

Hakimizadeh, E., Tadayon, S., Zamanian, M. Y., Soltani, A., Giménez-Llort, L., Hassanipour, M., & Fatemi, I. (2023). Gemfibrozil, a lipid‐lowering drug, improves hepatorenal damages in a mouse model of aging. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12865

Vancouver

Hakimizadeh E, Tadayon S, Zamanian MY, Soltani A, Giménez-Llort L, Hassanipour M, et al. Gemfibrozil, a lipid‐lowering drug, improves hepatorenal damages in a mouse model of aging. Fundamental & Clinical Pharmacology. 2023. doi:10.1111/fcp.12865

BibTeX
@article{Hakimizadeh2023,
  author = {Hakimizadeh, Elham and Tadayon, Saeedeh and Zamanian, Mohammad Yasin and Soltani, Afsaneh and Giménez-Llort, Lydia and Hassanipour, Mahsa and Fatemi, Iman},
  title = {Gemfibrozil, a lipid‐lowering drug, improves hepatorenal damages in a mouse model of aging},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/fcp.12865}
}
Kostenlos starten →